Reimbursement & Market Access
Timely Access to innovation
Ensuring timely patient access to medical technology innovations. We proactively address innovators’ challenges at CMS, with private payers, and other stakeholders to deliver the best health outcomes for patients and providers
Valley of Death
Medicare beneficiaries are denied access to FDA-authorized breakthrough technologies for years, a delay commonly referred to as the “valley of death”
Waiting 5.7 Years
Stanford researchers found beneficiaries wait over half a decade (5.7 yr median) before Medicare covers FDA authorized novel technologies
Solutions Exist
Enactment of H.R. 1691 and implementation of TCET will make a meaningful difference in the lives of Medicare beneficiaries
WHY REIMBURSEMENT MATTERS
Medical technology innovators’ guiding mission is to provide life-saving and life-changing products to patients who need them most while improving health outcomes across the country and around the world.
Challenges associated with establishing timely and adequate reimbursement often, and many times unnecessarily, delay patient access to innovative technologies, diagnostics, and digital services. MDMA works to align coding, coverage, and payment policies and procedures with government healthcare programs and private payers to help ensure patient access to safe and effective medical technology innovations. Without timely and adequate reimbursement in place, patients are denied access to the most effective medical treatments and care.
Click here for the latest Reimbursement & Market Access news.
“Lorem ipsum dolor sit amet, consectetur adipiscing elit. Praesent semper rutrum mollis. Aliquam in lectus a nisl rhoncus accumsan at non augue. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos.”
First Name Last Name Here | Title Name Here, Company Here